Psoriasis and Pustular Dermatitis Triggered by TNF-α Inhibitors in Patients With Rheumatologic Conditions | Zendy

Gillian C. de Gannes | Zendy; Mehran Ghoreishi | Zendy; Janet Pope | Zendy; Anthony S. Russell | Zendy; David Bell | Zendy; Stewart Adams | Zendy; Kam Shojania | Zendy; Magdalena Martinka | Zendy; Jan Dutz | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Psoriasis and Pustular Dermatitis Triggered by TNF-α Inhibitors in Patients With Rheumatologic Conditions

Author(s) -

Gillian C. de Gannes,

Mehran Ghoreishi,

Janet Pope,

Anthony S. Russell,

David Bell,

Stewart Adams,

Kam Shojania,

Magdalena Martinka,

Jan Dutz

Publication year - 2007

Publication title -

archives of dermatology

Language(s) - English

Resource type - Journals

eISSN - 1538-3652

pISSN - 0003-987X

DOI - 10.1001/archderm.143.2.223

Subject(s) - medicine , psoriasis , etanercept , psoriatic arthritis , infliximab , adalimumab , immunology , arthritis , tumor necrosis factor alpha , exacerbation , dermatology , alpha interferon , rheumatoid arthritis , interferon

New onset or worsening of psoriasis has been reported in patients treated with tumor necrosis factor alpha (TNF-alpha) inhibitors for a variety of rheumatologic conditions. There is mounting evidence that a key innate immune pathway for triggering common human autoimmune disease, including psoriasis, involves plasmacytoid dendritic cell precursors (PDCs) and type 1 interferon (IFN) production. We present herein a case series with clinical and histopathologic evidence of psoriasis in patients with rheumatologic disease treated with TNF-alpha inhibitors. We propose that the cross regulation between TNF-alpha and IFN may have a role in the pathogenesis of this reaction.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research